Vertex Pharmaceuticals stock gets lift from higher 2026 guidance

Vertex Pharmaceuticals reported third-quarter 2026 results on Monday, November 2, showing stronger sales and a broader commercial base while acquisition costs weighed on reported profit. In its financial release, the company said revenue for the period ended September 30 rose 12 percent year over year to USD 3.44 billion.

Vertex Pharmaceuticals stock traded at 505.85 euros on Lang & Schwarz at 14:11 CET on Tuesday, November 3, 2026. The quote places the stock in focus as investors assess whether growth from newer medicines can gradually reduce the company's dependence on cystic fibrosis treatments.

New products broaden the revenue base

Cystic fibrosis remained the core business, generating USD 3.27 billion in product revenue during the quarter, up from USD 3.04 billion a year earlier. ALYFTREK revenue rose to USD 705.8 million from USD 247.0 million, offsetting lower TRIKAFTA and KAFTRIO revenue of USD 2.44 billion compared with USD 2.65 billion in the prior-year quarter.

Vertex also reported increasing contributions from medicines outside cystic fibrosis. CASGEVY revenue reached USD 99.2 million, JOURNAVX generated USD 58.3 million, and PALSONIFY contributed USD 10.1 million after the Crinetics Pharmaceuticals acquisition closed on September 1. The company said it expects CASGEVY and JOURNAVX together to generate at least USD 500 million in 2026 revenue, while PALSONIFY is expected to contribute USD 40 million to USD 50 million for the year.

Management described the portfolio as increasingly diversified across cystic fibrosis, blood disorders, acute pain and rare endocrine diseases. The Crinetics deal established rare endocrinology as a fourth commercial area, while Vertex is preparing for a potential fifth franchise in kidney disease.

Guidance rises as costs increase

Vertex raised its full-year 2026 revenue guidance to USD 13.15 billion to USD 13.25 billion from the previous range of USD 13.1 billion to USD 13.2 billion. The increase primarily reflects the addition of Crinetics and its expected contribution to sales. The outlook also includes a foreign-exchange benefit of approximately 150 basis points.

Reported profitability was more mixed. GAAP net income fell to USD 653.6 million from USD 1.08 billion, mainly because of acquisition-related expenses. Non-GAAP net income was USD 1.21 billion, compared with USD 1.24 billion a year earlier, while non-GAAP diluted earnings per share declined to USD 4.76 from USD 4.80.

Vertex increased its full-year combined non-GAAP research and development, acquired in-process research and development, and selling, general and administrative expense outlook to approximately USD 6 billion from USD 5.65 billion to USD 5.75 billion previously. The company attributed the increase largely to Crinetics operating and integration costs, alongside investment in the renal franchise and the JOURNAVX launch.

FDA decision is the next catalyst

The US Food and Drug Administration is conducting a priority review of povetacicept for accelerated approval in immunoglobulin A nephropathy. Vertex said the assigned PDUFA target action date is November 30, 2026. If approved, the therapy would give the company a commercial entry into nephrology and add another potential growth pillar to its portfolio.

Vertex is also advancing studies in APOL1-mediated kidney disease, pain, diabetes, cystic fibrosis and rare endocrine disorders. Results from the AMPLITUDE study of inaxaplin are expected in early 2027, while the company expects to complete enrollment in late-stage pain studies by the end of 2026 and report results in 2027.

For investors, the earnings report points to a trade-off between healthy demand across the established franchise and the cost of building new commercial platforms. The raised revenue outlook supports the growth case, while the higher expense plan and acquisition-related charges make execution and launch uptake important factors for the next reporting periods. Follow the real-time quote of Vertex Pharmaceuticals stock for the latest trading indication.

Broader sentiment for US-listed healthcare companies can be tracked through the S&P 500 market environment.

Read more news and analyses on Vertex Pharmaceuticals stock.

Vertex Pharmaceuticals at a glance

• Company: Vertex Pharmaceuticals Incorporated
• ISIN: US92532F1003
• Ticker: VRTX
• Primary listing: Nasdaq
• Lang & Schwarz quote: 505.85 euros at 14:11 CET on November 3, 2026
• Third-quarter revenue: USD 3.44 billion, up 12 percent year over year
• 2026 revenue guidance: USD 13.15 billion to USD 13.25 billion
• Next major regulatory date: November 30, 2026, for povetacicept in immunoglobulin A nephropathy